Institutional investors purchased a net $25.4 thousand shares of BSTC during the quarter ended June 2017. This may signal that the smart money is gaining interest in this company as the 56.99% of the shares outstanding that institutional investors hold is among the lowest in the Pharmaceuticals: Other industry.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
STONEPINE CAPITAL MANAGEMENT LLC Bought 59.9 Thousand shares of Biospecifics Technologies...